PEMBR-01: Pembrolizumab in the Treatment of Advanced, Progressive Adrenocortical Carcinoma.
Study Details
Study Description
Brief Summary
This study is a national, multicenter, interventional, phase II clinical trial on the use of pembrolizumab in advanced adrenocortical carcinoma, with confirmed progression within 6 months, following EDP or EDP-M ( etoposide, doxorubicin, cisplatin- mitotan) chemotherapy.
Adrenocortical carcinoma is a very rare entity with poor prognosis and limited therapeutic options. Only radical surgical treatment of the early stages gives a chance for complete cure, however the risk of recurrence still remains high.
The results of clinical trials conducted outside Poland indicate a possible potential role of immunotherapy as a rescue treatment for adrenocortical carcinoma after standard therapeutic methods have been exhausted.
This study will evaluate the efficacy and tolerability of treatment with the immune checkpoint inhibitor pembrolizumab in locally advanced, non-operable or metastatic adrenocortical carcinoma after first line chemotherapy failure.
The study population will include adult patients (>18 years of age) with histopathologically confirmed adrenocortical carcinoma and confirmed progression according to RECIST 1.1 within 6 months, after first line chemotherapy with the EDP and EDP-M scheme. Patients must meet the inclusion criteria and must not meet the exclusion criteria described in the PEMBR-01 study protocol. The planned number of patients in the study is 24.
The treatment regimen will be based on Pembrolizumab administered intravenously in 3 weeks cycles at a dose of 200mg. For hormonally active tumors producing cortisol, it is hypothesized that the use of pembrolizumab in combination with effective steroidogenesis inhibition may enhance the effect of immunotherapy. In the study, metyrapone or ketoconazole will be used for this purpose.
The primary endpoint of the study will be the objective response rate to the treatment. The secondary endpoints will be progression-free survival, duration of response, overall survival, and treatment safety as well as the effect of therapy on patients' quality of life.
Concurrently, the analysis of biomarkers in tumor tissue will be carried out, including tumour infiltrating lymphocytes, expression of programmed death ligand, microsatellite instability and tumour mutation burden.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 2 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Pembrolizumab Treatment
|
Drug: Pembrolizumab 25 MG/ML [Keytruda]
The treatment scheme will be based on pembrolizumab administered intravenously in cycles of every 3 weeks 200 mg, with supportive treatment with steroidogenesis inhibitor (metyrapone or ketoconazole) for adrenocortical carcinoma producing cortisol.
|
Outcome Measures
Primary Outcome Measures
- Objective Response Rate [through study completion, an average of 4 years]
Percentage of patients who achieved a partial (PR) or complete (CR) response to treatment.
- Progression-Free Survival (PFS) [through study completion, an average of 4 years]
Time from first dose of treatment until disease progression or death from any cause.
- Duration of Response (DoR) [through study completion, an average of 4 years]
Duration of response to treatment (from the start of CR or PR) until disease progression or death from any cause.
- Overall Survival (OS) [through study completion, an average of 4 years]
Time from initiating treatment to death from any cause.
Secondary Outcome Measures
- Number of Adverse Events and Serious Adverse Events (AE and SAE) [through study completion, an average of 4 years]
Number of Adverse Events and Serious Adverse Events (AE and SAE) related and not related to treatment according to CTCAE.
- Quality of life assessed based on the QLQ-C30 questionnaire. [through study completion, an average of 4 years]
Quality of life assessed based on the QLQ-C30 questionnaire in which patients will respond during the clinical trial.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Signing the informed consent form to participate in the study
-
Age over 18 years of age
-
Histopathologically confirmed adrenocortical carcinoma
-
The general condition of the patient was assessed according to the Eastern Cooperative Oncology Group (ECOG) scale <2
-
Measurable disease according to RECIST 1.1
-
Confirmed progression according to RECIST 1.1 within the last 6 months in patients, who received at least one line chemotherapy according to the EDP or EDP-M
-
Adequate function of the marrow and internal organs:
-
hemoglobin ≥ 9g%, neutrophils> 1500 / mm3, platelets> 100 thousand / mm3
-
bilirubin ≤ 2 x upper limit of normal (UNL), Alat, Aspat ≤ 3 x UNL (if livermetastases are present ≤ 5 x UNL)
-
creatinine clearance > 40 ml / min
-
coagulation parameters: INR, PT, APTT <1.5 x UNL (exception: patients undergoing anticoagulation therapy, where INR, PT, APTT remain within the therapeutic range recommended for the patient)
-
For women of reproductive age : confirmed negative pregnancy test result, and the requirement of dual barrier contraception
-
For men of reproductive age: the requirement of dual barrier contraception
Exclusion Criteria:
-
Pre-treatment with an immune checkpoint inhibitor
-
Any cancer therapy within the last 7 days (including mitotane)
-
Persistent side effects of previous anti-cancer therapy in the> G1 stage or after surgical treatment (exception: alopecia)
-
Immunosuppressive therapy present or conducted within the last 4 weeks
-
Glucocorticoid therapy in a dose higher than the replacement dose (subject to the permitted use: inhaled or topical steroids, single administration of a steroid, e.g. in case of an allergic reaction to contrast, use of mineralocorticosteroids, steroids in the course of asthma or COPD)
-
Previous allograft marrow or organ transplant
-
Current or diagnosed in the last 2 years autoimmune disease with the exception of vitiligo, psoriasis not requiring systemic treatment, autoimmune disease of the thyroid gland
-
Active or previously documented inflammatory disease of the large intestine
-
Previous non-infectious pneumonia requiring steroid therapy
-
Hepatitis B or C
-
Active tuberculosis
-
Current active infection requiring systemic treatment
-
Symptomatic, untreated central nervous system (CNS) metastases (exception: patients with asymptomatic CNS metastases with prior surgery or radiotherapy and no history of intracranial bleeding)
-
Circulatory failure NYHA ≥3
-
Corrected QT interval> 500 ms
-
Significant coexisting disease, including neoplastic, except for basal cell carcinoma of the skin, carcinoma in situ: prostate, cervix, breast
-
Other significant comorbid disease that, in the investigator's opinion, would pose risks to the patient during therapy
-
Pregnancy or breastfeeding
-
Patients requiring dialysis
-
The patient's inability to meet the requirements specified in the study protocol
-
Vaccination with live vaccine within 3 months before starting treatment
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Maria Sklodowska-Curie National Research Institute of Oncology
- Biostat Sp. z o.o.
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- PEMBR-01